# Staar Surgical Co: Form 10-Q for the period ended Jul 2, 2021

- Company: [Staar Surgical Co](/companies/staa.md) (CIK 718937)
- Form: 10-Q
- Filed: 2021-08-04
- Accepted by EDGAR: Aug 4, 2021, 16:13 ET
- Period: 2021-07-02
- Accession: 0001564590-21-040819
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/718937/000156459021040819/staa-10q_20210702.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/718937/000156459021040819/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-07-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-03 to 2021-07-02 | $3.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-02 to 2021-07-02 | $7.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-03 to 2021-07-02 | $13.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-02 to 2021-07-02 | $24.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-03 to 2021-07-02 | $49.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-02 to 2021-07-02 | $88.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-03 to 2021-07-02 | $8.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-02 to 2021-07-02 | $16.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-04-03 to 2021-07-02 | $38.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2021-01-02 to 2021-07-02 | $70.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-03 to 2021-07-02 | $10.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-02 to 2021-07-02 | $18.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-03 to 2021-07-02 | $2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-02 to 2021-07-02 | $3.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-03 to 2021-07-02 | $8.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-02 to 2021-07-02 | $13.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-03 to 2021-07-02 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-02 to 2021-07-02 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-03 to 2021-07-02 | $0.18 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-02 to 2021-07-02 | $0.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-03 to 2021-07-02 | 49,491,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-02 to 2021-07-02 | 49,373,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-02 to 2021-07-02 | $13.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-02 to 2021-07-02 | $5.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-07-02 | $173.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-07-02 | $248.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-07-02 | $294.4m | us-gaap:Assets |
| Current liabilities | at 2021-07-02 | $41.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-07-02 | $59.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-07-02 | $234.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,754 characters.

*The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EVO Viva family of lenses for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2021 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.*

*Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 24, 2021. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.*

*The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.*

### Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (IOL) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our IOL lenses used in surgery that treats cataracts based on quality and value.

### Recent Developments

For the second quarter of 2021 STAAR’s net sales increased 77% over the prior year driven by 79% global ICL unit growth as markets continued to more fully reopen following COVID-19 related shutdowns and we continued to gain momentum towards realization of a lens-based future for refractive vision correction. Notable markets for ICL unit growth in the second quarter of 2021 included China, Japan, South Korea, APAC Distributor Markets, India, Spain, Germany, European Distributor Markets, the Middle East, and the U.S. In late April, the FDA received our clinical data for our EVO family of myopia lenses with the goal of bringing EVO to the U.S. market later this year. Our submission is currently under customary interactive FDA review. We are continuing the phased rollout of our EVO Viva lens, which is the presbyopia-correcting lens that received CE Mark approval in 2020.

While COVID-19 hotspots and government public health mandates may reoccur moving forward, we anticipate less business interruption and continued interest in our EVO ICL lens-based refractive solutions throughout 2021. Based on our first half 2021 financial results and with increasing visibility into key second half growth drivers for our business, we currently expect full year fiscal 2021 net sales to reach a range of $227 million to $230 million, up from our previously disclosed expectations for fiscal 2021 net sales of $215 million to $217 million.

### Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the six months ended July 2, 2021 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 1, 2021.

### Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Operations for the periods indicated.

|  | Percentage of Net Sales for Three Months July 2, 2021 | July 3, 2020 | Percentage of Net Sales for Six Months July 2, 2021 | July 3, 2020 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of sales | 21.1% | 30.6% | 21.9% | 30.1% |
| Gross profit | 78.9% | 69.4% | 78.1% | 69.9% |
| General and administrative | 18.4% | 22.3% | 19.1% | 22.5% |
| Selling and marketing | 30.2% | 29.3% | 28.4% | 30.3% |
| Research and development | 13.2% | 20.8% | 14.6% | 20.2% |
| Total selling, general and administrative | 61.8% | 72.4% | 62.1% | 73.0% |
| Operating income (loss) | 17.1% | (3.0)% | 16.0% | (3.1)% |
| Total other income (expense), net | 0.1% | 1.2% | (1.0)% | 0.4% |
| Income (loss) before income taxes | 17.2% | (1.8)% | 15.0% | (2.7)% |
| Provision (benefit) for income taxes | 3.5% | 1.5% | 3.0% | (0.8)% |
| Net income (loss) | 13.7% | (3.3)% | 12.0% | (1.9)% |

### Net Sales

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| ICLs | $59,235 | $30,728 | 92.8% | $105,736 | $60,068 | 76.0% |
| Other product sales: |  |  |  |  |  |  |
| IOLs | 3,074 | 2,561 | 20.0% | 6,799 | 6,555 | 3.7% |
| Other surgical products | 58 | 1,905 | (97.0)% | 584 | 3,758 | (84.5)% |
| Total other product sales | 3,132 | 4,466 | (29.9)% | 7,383 | 10,313 | (28.4)% |
| Net sales | $62,367 | $35,194 | 77.2% | $113,119 | $70,381 | 60.7% |

19

Net sales for the three months ended July 2, 2021 were $62.4 million, an increase of 77% from $35.2 million reported during the same period of 2020. The increase in net sales was due to increased ICL sales of $28.5 million, partially offset by a decrease in other product sales of $1.3 million. Changes in foreign currency favorably impacted net sales by $0.8 million.

Net sales for the six months ended July 2, 2021 were $113.1 million, an increase of 61% from $70.4 million reported during the same period of 2020. The increase in net sales was due to increased ICL sales of $45.7 million, partially offset by a decrease in other product sales of $2.9 million. Changes in foreign currency favorably impacted net sales by $1.9 million.

Total ICL sales for the three months ended July 2, 2021 were $59.2 million, an increase of 93% from $30.7 million reported for the same period of 2020, with unit increase of 79%. The APAC region sales increased by 80%, with unit growth up 68%, due to sales growth in India up 161%, other APAC Distributors up 116%, Japan up 92%, China up 79%, and Korea up 59%. The Europe, Middle East, Africa and Latin America region sales increased 129% with unit increase of 133%, due to sales growth in United Kingdom up 504%, Middle East and North Africa up 356%, Latin America up 186%, Spain up 135%, Distributor Operations up 95% and Germany up 76%. The North America region sales increased 230%, with unit increase of 266%, due increased sales in Canada up 339% and the U.S. up 216%. Second quarter 2021 sales growth continues to follow the third quarter 2020 sales growth trends experienced after the initial COVID-19 pandemic closures occurred in many of our primary markets during the first half of 2020. Changes in foreign currency favorably impacted ICL sales by $0.7 million for the three months ended July 2, 2021. ICL sales represented 95.0% and 87.3% of our total sales for the three months ended July 2, 2021 and July 3, 2020, respectively.

Total ICL sales for the six months ended July 2, 2021 were $105.7 million, an increase of 76% from $60.1 million reported for the same period of 2020, with unit increase of 67%. The APAC region sales increased by 72%, with unit growth up 64%, due to sales growth in India up 89%, Japan up 84%, other APAC Distributors up 78%, China up 74%, and Korea up 41%. The Europe, Middle East, Africa and Latin America region sales increased 84% with unit increase of 78%, due to sales growth in the United Kingdom up 148%, Latin America up 109%, Middle East and North Africa up 98%, Spain up 88%, Distributor Operations up 82% and Germany up 67%. The North America region sales increased 110%, with unit increase of 124%, due increased sales in Canada up 141% and the U.S. up 105%. First half 2021 sales growth continues to follow the third quarter 2020 sales growth trends experienced after the initial COVID-19 pandemic closures occurred in many of our primary markets during the first half of 2020. Changes in foreign currency favorably impacted ICL sales by $1.7 million for the six months ended July 2, 2021. ICL sales represented 93.5% and 85.3% of our total sales for the six months ended July 2, 2021 and July 3, 2020, respectively.

Other product sales, including IOLs were $3.1 million for the three months ended July 2, 2021, a decrease of 30% from $4.5 million reported for the same period of 2020 and were $7.4 million for the six months ended July 2, 2021, a decrease of 28% from $10.3 million reported for the same period of 2020. The decrease for both periods was due to product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers, as well as decreased IOL sales. Changes in foreign currency favorably impacted other product sales by $0.2 million for the six months ended July 2, 2021. Other product sales represented 5.0% and 12.7% of our total sales for the three months ended July 2, 2021 and July 3, 2020, respectively, and represented 6.5% and 14.7% of our total sales for the six months ended July 2, 2021 and July 3, 2020, respectively.

### Gross Profit

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | --- | ---: | ---: | ---: |
| Gross profit | $49,203 | $24,430 | —\* | $88,345 | $49,190 | 79.6% |
| Gross margin | 78.9% | 69.4% |  | 78.1% | 69.9% |  |

\* Denotes change is greater than +100%.

Gross profit for the three months ended July 2, 2021 was $49.2 million, a 101.4% increase compared to the $24.3 million reported for the same period of 2020. Gross profit margin increased to 78.9% of revenue for the three months ended July 2, 2021 compared to 69.4% of revenue for the three months ended July 3, 2020, due to geographic sales mix, a decreased mix of injector part sales which carry a lower margin, and for the three months ended July 3, 2020 there were $1.0 million period costs recorded as a result of COVID-19 and the resulting manufacturing pause from April 4 through April 27, 2020.

Gross profit for the six months ended July 2, 2021 was $88.3 million, a 79.6% increase compared to the $49.2 million reported for the same period of 2020. Gross profit margin increased to 78.1% of revenue for the six months ended

July 2, 2021 compared to 69.9% of revenue for the six months ended July 3, 2020, due to geographic sales mix, a decreased mix of injector part sales which carry a lower margin, and for the six months ended July 3, 2020 there were $1.2 million period costs recorded as a result of COVID-19 and the resulting manufacturing pause from March 17, 2020 through April 27, 2020.

### General and Administrative Expense

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative expense | $11,441 | $7,848 | 45.8% | $21,653 | $15,817 | 36.9% |
| Percentage of sales | 18.4% | 22.3% |  | 19.1% | 22.5% |  |

General and administrative expenses for the three months ended July 2, 2021 were $11.4 million, a 45.8% increase compared to the $7.8 million reported for the same period of 2020 due to increased compensation-related expenses, corporate insurance and facilities costs. General and administrative expenses for the six months ended July 2, 2021 were $21.7 million, a 36.9% increase compared to the $15.8 million reported for the same period of 2020 due to increased compensation-related expenses, corporate insurance and facility costs, partially offset by decreased tax consulting costs.

### Selling and Marketing Expense

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling and marketing expense | $18,853 | $10,326 | 82.6% | $32,054 | $21,354 | 50.1% |
| Percentage of sales | 30.2% | 29.3% |  | 28.4% | 30.3% |  |

Selling and marketing expenses for the three months ended July 2, 2021 were $18.9 million, a 82.6% increase compared to the $10.3 million reported for the same period of 2020 and for the six months ended July 2, 2021 were $32.1 million, a 50.1% increase compared to the $21.4 million reported for the same period of 2020. The increase in both periods was due to increased compensation-related expenses, advertising and promotional activities and trade shows expenses, and for the three months ended July 2, 2021, increased travel and entertainment expenses.

### Research and Development Expense

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development expense | $8,260 | $7,311 | 13.0% | $16,519 | $14,209 | 16.3% |
| Percentage of sales | 13.2% | 20.8% |  | 14.6% | 20.2% |  |

Research and development expenses for the three months ended July 2, 2021 were $8.3 million, a 13.0% increase compared to the $7.3 million reported for the same period of 2020 due to increased compensation-related expenses, partially offset by decreased clinical expenses associated with our EVO clinical trial in the U.S. Research and development expenses for the six months ended July 2, 2021 were $16.5 million, a 16.3% increase compared to the $14.2 million reported for the same period of 2020 due to increased compensation-related expenses.

### Other Income (Expense), Net

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | --- |
| Other income (expense), net | $66 | $439 | (85.0)% | $(1,165) | $282 | —\* |
| Percentage of sales | 0.1% | 1.2% |  | (1.0)% | 0.4% |  |

\* Denotes change is greater than +100%.

Other income, net for the three months ended July 2, 2021 was $0.1 million, an 85% decrease from $0.4 million reported for the same period of 2020, due to increased foreign exchange losses (primarily euro). Other expense, net for the six months ended July 2, 2021 was $1.2 million, compared to other income, net of $0.3 million reported for the same period of 2020. The change in other expense, net for the six months was due increased foreign exchange losses (primarily euro) and decreased interest income.

### Income Taxes

|  | Three Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | Percentage Change 2021 vs. 2020 |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Income tax provision (benefit) | $2,148 | $556 | —\* | $3,395 | $(602) | —\* |

\* Denotes change is greater than +100%.

We recorded income taxes of $2.1 million and $3.4 million for the three and six months ended July 2, 2021, respectively, due to pre-tax income generated in certain foreign jurisdictions and a recapture of our U.S. valuation allowance of $0.8 million as a result of increased tax deductions in the projection of taxable income used in our valuation assessment. The Company, from time to time may adjust the projections of taxable income as a result of current conditions. We recorded income taxes of $0.6 million for the three months ended July 3, 2020 due to pre-tax income generated in certain foreign jurisdictions. We recorded an income tax benefit of $0.6 million for the six months ended July 3, 2020 due to a release of our U.S. valuation allowance of $1.4 million, as a result of us revising our global forecasts in response to the impacts of COVID-19, and due to changes in the usage and release of certain deferred tax assets, offset by pre-tax income generated in certain foreign jurisdictions.

ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable. The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. We considered the projected future income, tax planning strategies and all other available evidence both positive and negative, as well as results of recent operations in making this assessment. The “incremental cash tax savings approach” is further described in Notes 1 and 10 of the Company’s fiscal 2020 Form 10-K. Under the incremental cash tax savings approach, our cumulative valuation allowance recorded was $37.3 million and $7.9 million for federal and state, respectively, at July 2, 2021, and $34.7 million and $7.4 million for federal and state, respectively, at January 1, 2021. Under the incremental cash tax savings approach, the valuation allowance recorded reflects the net operating losses and deferred tax assets which will not result in future cash tax savings and therefore provide no additional benefit. Total U.S. net deferred tax assets were $3.0 million and $3.9 million as of July 2, 2021 and January 1, 2021, respectively.

### Liquidity and Capital Resources

We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Although we have experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic in the first half of 2020, this has improved since the third quarter of 2020 as our customers resume elective refractive surgery. We are unaware of any impairment of assets resulting from the COVID-19 pandemic. The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and does not expect to do so given the strength of our balance sheet. Our financial condition at July 2, 2021 and January 1, 2021 included the following (in millions):

|  | July 2, 2021 | January 1, 2021 | 2021 vs. 2020 |
| --- | ---: | ---: | ---: |
| Cash and cash equivalents | $173.1 | $152.5 | $20.6 |
| Current assets | $248.1 | $216.4 | $31.7 |
| Current liabilities | 41.8 | 41.2 | 0.6 |
| Working capital | $206.3 | $175.2 | $31.1 |

We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. Additionally, at July 2, 2021, we have a line of credit with a Japanese lender, in the amount of $1.3 million, with $3.2 million of availability.

Net cash provided by operating activities was $13.1 million for the six months ended July 2, 2021 compared to net cash used by operating activities of $8.2 million for the six months ended July 3, 2020. Net cash provided by operating activities for the six months ended July 2, 2021, consisted of $13.6 million in net income, $11.5 in non-cash items, offset by $12.0 million in working-capital changes. The increase in net cash provided by operating activities during the six months ended July 2, 2021 was due to increased non-cash items of $3.7 million, net working capital of $2.7 million and net income of $13.6 million for the six months ended July 2, 2021 compared to a net loss of $1.3 million for the six months ended July 3, 2020.

Net cash used in investing activities was $5.7 million and $4.2 million for the six months ended July 2, 2021 and July 3, 2020, respectively, and relate primarily to the acquisition of property, plant, and equipment.

Net cash provided by financing activities was $13.8 million and $8.7 million for the six months ended July 2, 2021 and July 3, 2020, respectively. Net cash provided by financing activities for the six months ended July 2, 2021 consisted of $14.1 million of proceeds from the exercise of stock options, partially offset by $0.3 million repayment of finance lease obligations.

### Credit Facilities and Commitments

#### Lines of Credit and Leases

See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.

#### Covenant Compliance

The Company is in compliance with the covenants of its credit facilities as of July 2, 2021.

#### Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

## Market risk

As filed, 236 characters.

During the six months ended July 2, 2021, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 1, 2021.

## Controls and procedures

As filed, 3,360 characters.

### Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended July 2, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 450 characters.

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 1, 2021. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.

Filed Aug 4, 2021.
Source: SEC EDGAR, the filing index for accession 0001564590-21-040819. Last ingested by Listed: Nov 4, 2026, 17:00 ET. No prices; not investment advice.
